Pliant Therapeutics Stock Performance
| PLRX Stock | USD 1.54 0.02 1.32% |
The company holds a Beta of 3.26, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pliant Therapeutics will likely underperform. At this point, Pliant Therapeutics has a negative expected return of -2.26%. Please make sure to check Pliant Therapeutics' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Pliant Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Pliant Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Disposition of 10230 shares by Mike Ouimette of Pliant Therapeutics at 10.9934 subject to Rule 16b-3 | 01/22/2025 |
2 | Pliant Therapeutics, Inc. General Counsel Mike Ouimette Sells 13,270 Shares of Stock | 01/23/2025 |
3 | Acquisition by Lefebvre Eric of 91300 shares of Pliant Therapeutics at 11.14 subject to Rule 16b-3 | 01/27/2025 |
4 | Pliant Therapeutics Announces Next Steps Following DSMB Recommendationon BEACON-IPF, a Phase 2b3 Trial in Patients with Idiopathic Pulmonary Fibrosis | 02/13/2025 |
5 | All You Need to Know About PLIANT THERAPT Rating Upgrade to Buy | 02/14/2025 |
6 | Acquisition by Lefebvre Eric of 45650 shares of Pliant Therapeutics subject to Rule 16b-3 | 02/26/2025 |
7 | Bronstein, Gewirtz Grossman, LLC Encourages Pliant Therapeutics, Inc. Shareholders to Inquire about Securities Investigation - Markets Insider | 02/27/2025 |
8 | Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b3 Trial in Patients with Idiopathic Pulmonary Fibrosis | 03/03/2025 |
9 | Pliant Therapeutics Neutral Rating Reiterated at Cantor Fitzgerald | 03/04/2025 |
10 | Wells Fargo Company Issues Pessimistic Forecast for Pliant Therapeutics Stock Price | 03/05/2025 |
11 | Acquisition by Coulie Bernard of 325000 shares of Pliant Therapeutics at 11.14 subject to Rule 16b-3 | 03/12/2025 |
12 | Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement | 03/13/2025 |
| Begin Period Cash Flow | 64.7 M |
Pliant |
Pliant Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,372 in Pliant Therapeutics on December 16, 2024 and sell it today you would lose (1,218) from holding Pliant Therapeutics or give up 88.78% of portfolio value over 90 days. Pliant Therapeutics is currently does not generate positive expected returns and assumes 12.9258% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Pliant, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pliant Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pliant Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pliant Therapeutics, and traders can use it to determine the average amount a Pliant Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1746
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PLRX |
Estimated Market Risk
| 12.93 actual daily | 96 96% of assets are less volatile |
Expected Return
| -2.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pliant Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pliant Therapeutics by adding Pliant Therapeutics to a well-diversified portfolio.
Pliant Therapeutics Fundamentals Growth
Pliant Stock prices reflect investors' perceptions of the future prospects and financial health of Pliant Therapeutics, and Pliant Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pliant Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (201.23 M) | ||||
| Shares Outstanding | 61.24 M | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 3,072 X | ||||
| EBITDA | (228.37 M) | ||||
| Net Income | (210.3 M) | ||||
| Cash And Equivalents | 163.6 M | ||||
| Cash Per Share | 3.36 X | ||||
| Total Debt | 29.98 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 7.69 X | ||||
| Book Value Per Share | 5.00 X | ||||
| Cash Flow From Operations | (155.5 M) | ||||
| Earnings Per Share | (3.47) X | ||||
| Market Capitalization | 94.3 M | ||||
| Total Asset | 396.95 M | ||||
| Retained Earnings | (710.05 M) | ||||
| Working Capital | 329.05 M | ||||
About Pliant Therapeutics Performance
Evaluating Pliant Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pliant Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pliant Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.56) | |
| Return On Capital Employed | (0.63) | (0.66) | |
| Return On Assets | (0.53) | (0.56) | |
| Return On Equity | (0.69) | (0.66) |
Things to note about Pliant Therapeutics performance evaluation
Checking the ongoing alerts about Pliant Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pliant Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pliant Therapeutics generated a negative expected return over the last 90 days | |
| Pliant Therapeutics has high historical volatility and very poor performance | |
| Pliant Therapeutics may become a speculative penny stock | |
| Pliant Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (210.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pliant Therapeutics currently holds about 163.6 M in cash with (155.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pliant Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement |
- Analyzing Pliant Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pliant Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pliant Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pliant Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pliant Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pliant Therapeutics' stock. These opinions can provide insight into Pliant Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.